Literature DB >> 27214077

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.

M Christopeit1, A Badbaran1, T Zabelina1, G Zeck1, B Fehse1, F Ayuk1, C Wolschke1, N Kröger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27214077     DOI： 10.1038/bmt.2016.128

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Regression modeling of competing risk using R: an in depth guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

2.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

3.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

4.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Authors:  A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

5.  Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  V Panagiota; F Thol; B Markus; B Fehse; H Alchalby; A Badbaran; U Lehmann; C Koenecke; R Shahswar; A Chaturvedi; M Stadler; M Eder; G Göhring; M Koenigsmann; A Kloos; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; H-H Kreipe; A Ganser; N Kröger; M Heuser
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

6.  Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation.

Authors:  A Badbaran; B Fehse; M Christopeit; T Aranyossy; F A Ayuk; C Wolschke; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Nicolaus Kröger; Ernst Holler; Guido Kobbe; Martin Bornhäuser; Rainer Schwerdtfeger; Herrad Baurmann; Arnon Nagler; Wolfgang Bethge; Matthias Stelljes; Lutz Uharek; Hannes Wandt; Andreas Burchert; Paolo Corradini; Jörg Schubert; Martin Kaufmann; Peter Dreger; Gerald G Wulf; Hermann Einsele; Tatjana Zabelina; Hans Michael Kvasnicka; Jürgen Thiele; Ronald Brand; Axel R Zander; Dietger Niederwieser; Theo M de Witte
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.